<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: following risks actually", fill: "#da9100"},
{source: "2: following risks actually", target: "2: financial condition", fill: "#da9100"},
{source: "2: financial condition", target: "2: operations", fill: "#da9100"},
{source: "2: operations", target: "2: future growth prospects would", fill: "#da9100"},
{source: "2: future growth prospects would", target: "2: materially", fill: "#da9100"},
{source: "2: materially", target: "2: adversely affected", fill: "#da9100"},
{source: "2: following risks actually", target: "4: dependent on", fill: "#ec5800"},
{source: "4: dependent on", target: "4: product discovery", fill: "#ec5800"},
{source: "4: product discovery", target: "4: commercialize", fill: "#ec5800"},
{source: "4: commercialize", target: "4: flavors flavor enhancers", fill: "#ec5800"},
{source: "4: flavors flavor enhancers", target: "4: modulators", fill: "#ec5800"},
{source: "4: modulators", target: "4: may discover", fill: "#ec5800"},
{source: "4: dependent on", target: "5: commercialize", fill: "#98ff98"},
{source: "5: commercialize", target: "5: flavors flavor", fill: "#98ff98"},
{source: "5: flavors flavor", target: "5: enhancers", fill: "#98ff98"},
{source: "5: enhancers", target: "5: modulators through product discovery", fill: "#98ff98"},
{source: "5: modulators through product discovery", target: "5: development", fill: "#98ff98"},
{source: "5: development", target: "5: collaborations", fill: "#98ff98"},
{source: "5: commercialize", target: "7: Substantially ", fill: "#673147"},
{source: "7: Substantially ", target: "7: future will", fill: "#673147"},
{source: "7: future will", target: "7: payments from", fill: "#673147"},
{source: "7: payments from", target: "7: collaborations", fill: "#673147"},
{source: "7: collaborations", target: "7: successfully commercialize", fill: "#673147"},
{source: "7: successfully commercialize", target: "7: product candidate through", fill: "#673147"},
{source: "7: product candidate through", target: "7: collaborators", fill: "#673147"},
{source: "7: collaborators", target: "7: earn royalties on future sales", fill: "#673147"},
{source: "7: earn royalties on future sales", target: "7: consumer products", fill: "#673147"},
{source: "7: consumer products", target: "7: incorporating", fill: "#673147"},
{source: "7: incorporating", target: "7: flavors flavor enhancers", fill: "#673147"},
{source: "7: flavors flavor enhancers", target: "7: modulators", fill: "#673147"},
{source: "7: Substantially ", target: "START_HERE", fill: "#673147"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Flavored_tobacco">Flavored tobacco</a></td>
      <td>A flavored tobacco product is a tobacco product with added flavorings. Flavored tobacco products include types of cigarettes, cigarillos and cigars, hookahs and hookah tobacco, various types of smokeless tobacco, and more recently electronic cigarettes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Flavor_of_Love_(season_1)">Flavor of Love (season 1)</a></td>
      <td>The first season of the VH1 reality television series Flavor of Love brings female contestants into the mansion of Flavor Flav to compete for his love. It aired weekly from January 1, 2006 to April 2, 2006, with a total of ten episodes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Flavor_of_the_Weak">Flavor of the Weak</a></td>
      <td>"Flavor of the Weak" is a song by American rock band American Hi-Fi. The song was released as the first single from their self-titled debut album on December 22, 2000.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Glutamate_flavoring">Glutamate flavoring</a></td>
      <td>Glutamate flavoring is the generic name for flavor-enhancing compounds based on glutamic acid and its salts (glutamates). These compounds provide an umami (savory) taste to food.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vanilla">Vanilla</a></td>
      <td>Vanilla is a spice derived from orchids of the genus Vanilla, primarily obtained from pods of the Mexican species, flat-leaved vanilla (V. planifolia). The word vanilla, derived from vainilla, the diminutive of the Spanish word vaina (vaina itself meaning a sheath or a pod), is translated simply as "little pod".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Taste">Taste</a></td>
      <td>The gustatory system or sense of taste is the sensory system that is partially responsible for the perception of taste (flavor). Taste is the perception produced or stimulated when a substance in the mouth reacts chemically with taste receptor cells located on taste buds in the oral cavity, mostly on the tongue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allosteric_modulator">Allosteric modulator</a></td>
      <td>In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimulus. Some of them, like benzodiazepines, are drugs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Receptor_modulator">Receptor modulator</a></td>
      <td>A receptor modulator, or receptor ligand, is a general term for a substance, endogenous or exogenous, that binds to and regulates the activity of chemical receptors. They are ligands that can act on different parts of receptors and regulate activity in a positive, negative, or neutral direction with varying degrees of efficacy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/RF_modulator">RF modulator</a></td>
      <td>An RF modulator (or radio frequency modulator) is an electronic device whose input is a baseband signal which is used to modulate a radio frequency source.RF modulators are used to convert signals from devices such as media players, VCRs and game consoles to a format that can be handled by a device designed to receive a modulated RF input, such as a radio or television receiver.\n\n\n== History ==\nPrior to the introduction of specialised video connector standards such as SCART, TVs were designed to only accept signals through the aerial connector: signals originate at a TV station, are transmitted over the air, and are then received by an antenna and demodulated within the TV. When equipment was developed which could use a television receiver as its display device, such as VCRs, DVD players, early home computers, and video game consoles, the signal was modulated and sent to the RF input connector.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Optical_modulator">Optical modulator</a></td>
      <td>An optical modulator is a device which is used to modulate a beam of light. The beam may be carried over free space, or propagated through an optical waveguide (optical fibre).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reuptake_modulator">Reuptake modulator</a></td>
      <td>A reuptake modulator, or transporter modulator, is a type of drug which modulates the reuptake of one or more neurotransmitters via their respective neurotransmitter transporters. Examples of reuptake modulators include reuptake inhibitors (transporter blockers) and reuptake enhancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Modulated_ultrasound">Modulated ultrasound</a></td>
      <td>Ultrasound can be modulated to carry an audio signal (like radio signals are modulated). This is often used to carry messages underwater, in underwater diving communicators, and short-range (under five miles) communication with submarines; the received ultrasound signal is decoded into audible sound by a modulated-ultrasound receiver.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Channel_modulator">Channel modulator</a></td>
      <td>A channel modulator, or ion channel modulator, is a type of drug which modulates ion channels. They include channel blockers and channel openers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Selective_androgen_receptor_modulator">Selective androgen receptor modulator</a></td>
      <td>Selective Androgen Receptor Modulators or SARMs are a class of androgen receptor ligands that maintain some of the desirable effects of androgens, such as preventing osteoporsis and muscle loss while reducing risks of developing prostate cancer.  In the last 1990s, the first nonsteroidal SARM, an analog of bicalutamide, was discovered.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_modulator">Gonadotropin-releasing hormone modulator</a></td>
      <td>A GnRH modulator, or GnRH receptor modulator, also known as an LHRH modulator or LHRH receptor modulator, is a type of medication which modulates the GnRH receptor, the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH; also known as luteinizing-releasing hormone, or LHRH). They include GnRH agonists and GnRH antagonists.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Performance-enhancing_substance">Performance-enhancing substance</a></td>
      <td>Performance-enhancing substances, also known as performance-enhancing drugs (PEDs), are substances that are used to improve any form of activity performance in humans. A well-known example involves doping in sport, where banned physical performance-enhancing drugs are used by athletes and bodybuilders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Endocannabinoid_enhancer">Endocannabinoid enhancer</a></td>
      <td>An endocannabinoid enhancer (eCBE) is a type of cannabinoidergic drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids. Examples of different types of eCBEs include fatty acid amide hydrolase (FAAH) inhibitors, monoacylglycerol lipase (MAGL) inhibitors, and endocannabinoid transporter (eCBT) inhibitors (or "endocannabinoid reuptake inhibitors" ("eCBRIs")).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Super-enhancer">Super-enhancer</a></td>
      <td>In genetics, a super-enhancer is a region of the mammalian genome comprising multiple enhancers that is collectively bound by an array of transcription factor proteins to drive transcription of genes involved in cell identity.  Because super-enhancers are frequently identified near genes important for controlling and defining cell identity, they may thus be used to quickly identify key nodes regulating cell identity.Enhancers have several quantifiable traits that have a range of values, and these traits are generally elevated at super-enhancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reuptake_enhancer">Reuptake enhancer</a></td>
      <td>A reuptake enhancer (RE), also sometimes referred to as a reuptake activator, is a type of reuptake modulator which enhances the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron, leading to a decrease in the extracellular concentrations of the neurotransmitter and therefore a decrease in neurotransmission.\nThe antidepressant tianeptine was once claimed to be a (selective) serotonin reuptake enhancer (SRE or SSRE), but the role of serotonin reuptake in its mechanism is doubtful.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Enhancer_RNA">Enhancer RNA</a></td>
      <td>Enhancer RNAs (eRNAs) represent a class of relatively long non-coding RNA molecules (50-2000 nucleotides) transcribed from the DNA sequence of enhancer regions. They were first detected in 2010 through the use of genome-wide techniques such as RNA-seq and ChIP-seq.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nootropic">Nootropic</a></td>
      <td>Nootropics ( noh-ə-TROHP-iks, or  noh-ə-TROP-iks) (colloquial: smart drugs and cognitive enhancers) are drugs, supplements, and other substances that are claimed to improve cognitive function, particularly executive functions, attention, memory, creativity, or motivation, in healthy individuals.The use of cognition-enhancing drugs by healthy individuals in the absence of a medical indication spans numerous controversial issues, including the ethics and fairness of their use, concerns over adverse effects, and the diversion of prescription drugs for non-medical uses.  Nonetheless, the international sales of cognition-enhancing supplements have continued to grow over time, and reached US$1.96 billion in 2018.In 2018 in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SENOMYX INC      Item 1A Risk Factors         You should consider <font color="blue">carefully</font> the following information about the risks     described below, <font color="blue">together with</font> the other information contained in this     annual report on Form 10-K and in our other <font color="blue">public filings</font>, in evaluating     our business</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occurs, our business,     <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and <font color="blue">future growth prospects would</font>     likely be <font color="blue">materially</font> and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>In these <font color="blue">circumstances</font>, the     <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> would likely decline</font></td>
    </tr>
    <tr>
      <td>Risks Related To Our Business         We are <font color="blue">dependent on</font> our <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> for     all  of our revenue and we are <font color="blue">dependent on</font> our current and any future     <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> to develop and <font color="blue">commercialize</font>     any flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> we <font color="blue">may discover</font></td>
    </tr>
    <tr>
      <td>A  key element of our strategy is to <font color="blue">commercialize</font> our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> through <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font>     <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>To date, all of our revenue has <font color="blue">been derived solely from</font>     research and <font color="blue">development</font> payments and <font color="blue">milestone payments</font> received under     <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font>s with</font> Cadbury Schweppes, Campbell Soup, Coca-Cola,     <font color="blue">Kraft Foods </font>and Nestle</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our revenue in the foreseeable     <font color="blue">future will</font> result from these types of <font color="blue">payments from</font> these <font color="blue"><font color="blue">collaboration</font>s</font>,     unless we <font color="blue">successfully</font> <font color="blue">commercialize</font> a <font color="blue">product candidate through</font> these or     other <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">earn royalties on future sales</font> of <font color="blue">consumer products</font>     <font color="blue">incorporating</font> our flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font>, as amended, with <font color="blue">Campbell Soup </font>provides for research and     <font color="blue">development</font> <font color="blue">funding until</font> March 2009 and gives <font color="blue">Campbell Soup </font>the right to     terminate  the <font color="blue">agreement</font> earlier without cause, provided that it pay a     specified <font color="blue">termination</font> fee if it terminates the <font color="blue">agreement</font> prior to March 28,     2009</td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font> with Coca-Cola provides for research and <font color="blue">development</font>     <font color="blue">funding until</font> April 2008, and gives Coca-Cola the right to conclude the     <font color="blue">collaborative</font>  program  earlier for any <font color="blue">reason upon payment</font> to us of a     <font color="blue">termination</font> fee, provided that Coca-Cola <font color="blue">may terminate</font> the <font color="blue">collaborative</font>     <font color="blue">period without payment</font> of an <font color="blue">early conclusion fee</font> in the event that we fail     to achieve a <font color="blue">specified research</font> and <font color="blue">development</font> goal by April 22, 2006,     subject to payment of <font color="blue">research funding through</font> July 22, 2006</td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font>     with  Kraft  Foods provides for research and <font color="blue">development</font> <font color="blue">funding until</font>     <font color="blue">December </font>2008, and gives <font color="blue">Kraft Foods </font>the right to conclude the <font color="blue">agreement</font>     earlier for any <font color="blue">reason upon payment</font> to us of a <font color="blue">termination</font> fee</td>
    </tr>
    <tr>
      <td>Our initial     <font color="blue">agreement</font> with Nestle (as amended in April 2005) provides for research and     <font color="blue">development</font>  funding  through April 2008 and gives Nestle the right to     terminate the <font color="blue">agreement</font> earlier without cause on or after April 18, 2006,     provided that it pay additional <font color="blue">specified research</font> funding if it terminates     the <font color="blue">agreement</font> after April 18, 2006 but prior to April 18, 2008</td>
    </tr>
    <tr>
      <td>Our most     recent <font color="blue">agreement</font> with Nestle provides for research and <font color="blue">development</font> funding     through October 2009 and gives Nestle the right to terminate the <font color="blue">agreement</font>     earlier without cause on or after October 26, 2006, provided that it pay     additional <font color="blue">specified research</font> funding if it terminates the <font color="blue">agreement</font> after     October 26, 2006 but prior to October 26, 2009</td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font> with Cadbury     Schweppes provides for research and <font color="blue">development</font> funding through July 2007,     and gives <font color="blue">Cadbury Schweppes </font>the right to terminate the <font color="blue">agreement</font> earlier     without cause on or after April 15, 2006 upon 90 days’ written notice</td>
    </tr>
    <tr>
      <td>If     any or all of our material <font color="blue">agreement</font>s with our <font color="blue"><font color="blue">collaborator</font>s</font> expire or are     terminated,  our <font color="blue">revenue would</font> <font color="blue"><font color="blue">significant</font>ly</font> decline and if all of our     <font color="blue">agreement</font>s expire or are terminated, our <font color="blue">revenue would</font> be <font color="blue">substantially</font>     eliminated, which would have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborator</font>s</font> may not     renew their <font color="blue">agreement</font>s with us or, if they do, they may not be on terms that     are as favorable to us as our current <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Our current <font color="blue">collaboration</font> <font color="blue">agreement</font>s provide that we will receive royalties     of up to 4prca on our <font color="blue"><font color="blue">collaborator</font>s</font>’ sales of <font color="blue">products containing</font> our flavors,     flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">actual royalties payable vary by</font>     <font color="blue">agreement</font> and <font color="blue">depend on</font> a number of factors including, for example, the     product field, cost of goods savings, degree of <font color="blue">flavor enhancement</font> and sales     volume of <font color="blue">collaborator</font> products <font color="blue">incorporating</font> our <font color="blue">flavor ingredients</font></td>
    </tr>
    <tr>
      <td>It is     possible that our <font color="blue"><font color="blue">collaborator</font>s</font> will not <font color="blue">incorporate</font> our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> into any or all of their <font color="blue">products within</font>     their <font color="blue">exclusive product fields</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________         We do not currently have a <font color="blue">commercialize</font>d product and <font color="blue">cannot assure</font> you we     will have a <font color="blue">commercialize</font>d product in the <font color="blue">foreseeable future</font>, or at all</td>
    </tr>
    <tr>
      <td>We     will be <font color="blue">dependent on</font> our current and any other possible future <font color="blue"><font color="blue">collaborator</font>s</font>     to <font color="blue">commercialize</font> any flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> that we     <font color="blue">successfully</font> develop and to provide the sales, marketing and <font color="blue">distribution</font>     <font color="blue">capabilities</font> required for the success of our business</td>
    </tr>
    <tr>
      <td>We have limited or no     <font color="blue">control over</font> the amount and timing of resources that our current or any     future <font color="blue"><font color="blue">collaborator</font>s</font> may devote to our programs or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">collaborator</font>s</font>  may decide not to devote the <font color="blue"><font color="blue">necessary</font> resources</font> to the     <font color="blue">commercialization</font> of our flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font>, or     may pursue a competitor’s product if our flavors, flavor <font color="blue">enhancers</font> or taste     <font color="blue">modulators</font> do not have the <font color="blue">characteristics</font> desired by the <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">characteristics</font> include, among other things, enhancement properties,     temperature stability, solubility, taste and cost</td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue">collaborator</font>s</font>     fail to conduct their <font color="blue">commercialization</font>, sales and marketing or <font color="blue">distribution</font>     <font color="blue">activities <font color="blue">successfully</font></font> and in a <font color="blue">timely manner</font>, we will earn little or no     <font color="blue"><font color="blue">royalty revenue</font>s from</font> our flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> and     we will not be able to achieve our <font color="blue">objectives</font> or build a sustainable or     profitable business</td>
    </tr>
    <tr>
      <td>Our present and any future <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue">collaboration</font>     <font color="blue"><font color="blue">opportunities</font> could</font> be harmed if:         •                  our existing or any future <font color="blue"><font color="blue">collaborator</font>s</font> terminate their     <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font>s with</font> us prior to the expiration of the <font color="blue">agreement</font>s;       •                  we do not achieve our research and <font color="blue">development</font> <font color="blue">objectives</font>     under  our  <font color="blue">collaboration</font>  <font color="blue">agreement</font>s  prior to the <font color="blue">termination</font> of the     <font color="blue">collaboration</font> periods;       •                  we <font color="blue">disagree with</font> our <font color="blue"><font color="blue">collaborator</font>s</font> as to the parties’     <font color="blue">respective licensing rights</font> to our flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font>, methods or other <font color="blue"><font color="blue">intellectual</font> property</font> we develop;       •                   we  are  unable  to  manage  <font color="blue">multiple simultaneous</font>     <font color="blue"><font color="blue">collaboration</font>s</font>;       •                  potential <font color="blue"><font color="blue">collaborator</font>s</font> fail to spend their <font color="blue">resources on</font>     research  and  <font color="blue">development</font> or <font color="blue">commercialization</font> of our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> due to <font color="blue">general market conditions</font> or for any     other reason; or       •                  <font color="blue">consolidation</font> in our <font color="blue">target markets limits</font> the number of     potential <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be able to negotiate additional <font color="blue">collaboration</font> <font color="blue">agreement</font>s having     terms satisfactory to us or at all</td>
    </tr>
    <tr>
      <td>We  may  not  be  able  to <font color="blue">enter into</font> additional <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font>  <font color="blue"><font color="blue">collaboration</font>s</font> due to the exclusive nature of our current     product  <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>Each of our current     <font color="blue">collaboration</font>  <font color="blue">agreement</font>s  provides  that we will conduct research and     <font color="blue">development</font> on flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> for use within     one  or  more  defined <font color="blue">packaged food</font> and beverage product fields on an     exclusive basis for the respective <font color="blue">collaborator</font> during the <font color="blue">collaborative</font>     <font color="blue">period specified</font> in the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Because each of these <font color="blue">agreement</font>s is     exclusive or co-exclusive, we will not be able to <font color="blue">enter into</font> a <font color="blue">collaboration</font>     <font color="blue">agreement</font> with any other food and <font color="blue">beverage company covering</font> the <font color="blue">same product</font>     field  during  the  applicable  <font color="blue">collaborative</font> period</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue"><font color="blue">collaborator</font>s</font>’ <font color="blue">competitors</font> may not wish to do business <font color="blue">with us at</font> all due to     our <font color="blue"><font color="blue">relationship</font> with</font> our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font>     additional <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font>, our ability to     sustain or expand our business will be <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> diminished</font></td>
    </tr>
    <tr>
      <td>We may not be successful in developing flavors, flavor <font color="blue">enhancers</font> or taste     <font color="blue">modulators</font> useful for <font color="blue">formulation <font color="blue">into products</font></font></td>
    </tr>
    <tr>
      <td>We  may  not  succeed in developing flavors, flavor <font color="blue">enhancers</font> or taste     <font color="blue">modulators</font> with the <font color="blue">appropriate attributes</font> required for use in successful     commercial  products</td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font>flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font> require, among other things, appropriate biological activity,     including the correct flavor or <font color="blue"><font color="blue">flavor enhancer</font> property</font> for the product     <font color="blue">application</font>, an acceptable <font color="blue">safety profile</font>, including lack of toxicity or     <font color="blue">allergenicity</font>, and <font color="blue">appropriate physical</font> or <font color="blue">chemical properties</font>, including     <font color="blue">relative levels</font> of stability, volatility and resistance to heat</td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font>   flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> must also be cost-efficient     for  our  <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be able to develop flavors, flavor     <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> that meet these criteria</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________         If  we or our <font color="blue"><font color="blue">collaborator</font>s</font> are unable to obtain and maintain the GRAS     de<font color="blue">termination</font> or <font color="blue"><font color="blue">regulatory</font> approval</font> required before any flavors, flavor     <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> can be <font color="blue">incorporate</font>d <font color="blue">into products</font> that are     sold, we would be unable to <font color="blue">commercialize</font> our flavors, flavor <font color="blue">enhancers</font> and     taste <font color="blue">modulators</font> and our business would be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>In March 2005, we obtained a GRAS de<font color="blue">termination</font> for four of our savory     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Apart from these <font color="blue">product <font color="blue">candidates</font></font>, we do not have GRAS     de<font color="blue">termination</font> or <font color="blue"><font color="blue">regulatory</font> approval</font> for any other <font color="blue">product candidate at</font> this     time</td>
    </tr>
    <tr>
      <td>In the United States, the <font color="blue">development</font>, sale and <font color="blue">incorporation</font> of our     flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> <font color="blue">into products</font> are subject to     regulation by FDA and in some instances other <font color="blue">government bodies</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Obtaining </font>    </font>and maintaining a GRAS de<font color="blue">termination</font> or <font color="blue"><font color="blue">regulatory</font> approval</font> can be costly     and take many years</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>on the amount or <font color="blue">intended use</font> of a particular flavor, flavor     enhancer or taste <font color="blue">modulator added</font> to a product and the number of product     <font color="blue">categories</font> in which the flavor, <font color="blue">flavor enhancer</font> or taste <font color="blue">modulator will</font> be     <font color="blue">incorporate</font>d, specific safety <font color="blue">assessment</font> protocols and <font color="blue"><font color="blue">regulatory</font> processes</font>     must be satisfied before we or our <font color="blue"><font color="blue">collaborator</font>s</font> can <font color="blue">commercially market</font> and     sell <font color="blue">products containing</font> any flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font>     that we <font color="blue">may discover</font></td>
    </tr>
    <tr>
      <td>A key element of our strategy is to develop flavors,     flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> that will be subject to <font color="blue">review under</font>     the  <font color="blue">FEMA GRAS </font>process, which, based on our experience with the savory     program, we expect will take approximately 12 months and is <font color="blue">less expensive</font>     than  the <font color="blue">alternative</font> of filing a <font color="blue">food additive petition with</font> the FDA,     approval of which can take <font color="blue">eight years</font> or more</td>
    </tr>
    <tr>
      <td>The <font color="blue">FEMA GRAS </font><font color="blue">review process</font>     may take longer than 12 months and cost more than dlra1 million depending on     the properties of the flavor, <font color="blue">flavor enhancer</font> or taste modulator, and if     <font color="blue">additional <font color="blue">safety studies</font></font> are <font color="blue">requested by</font> the <font color="blue">FEMA Expert Panel </font>or are     <font color="blue">necessary</font> to explain unexpected safety study findings</td>
    </tr>
    <tr>
      <td>There is a risk that     one  or more of our <font color="blue">product <font color="blue">candidates</font></font> may not qualify for a <font color="blue">FEMA GRAS </font>    de<font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>This may occur for a variety of reasons, including the     flavor, <font color="blue">flavor enhancer</font> or taste modulator’s <font color="blue">intended use</font>, the amount of the     flavor, <font color="blue">flavor enhancer</font> or taste <font color="blue">modulator intended</font> to be added to packaged     foods and beverages, the number of product <font color="blue">categories</font> in which the flavor,     <font color="blue">flavor enhancer</font> or taste <font color="blue">modulator will</font> be <font color="blue">incorporate</font>d, whether the flavor,     <font color="blue">flavor enhancer</font> or taste <font color="blue">modulator imparts sweetness</font>, the <font color="blue">safety profile</font> of     the flavor, <font color="blue">flavor enhancer</font> or taste modulator and the FEMA Expert Panel’s     <font color="blue">interpretation</font> of the <font color="blue">safety data</font></td>
    </tr>
    <tr>
      <td>Even if we obtain a GRAS de<font color="blue">termination</font>     <font color="blue">with respect</font> to a flavor, <font color="blue">flavor enhancer</font> or taste modulator, the FDA has     the  ability  to  challenge such de<font color="blue">termination</font>, <font color="blue">which could</font> <font color="blue">materially</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue">market products on schedule</font> or at all</td>
    </tr>
    <tr>
      <td>In     the event that a particular flavor, <font color="blue">flavor enhancer</font> or taste modulator does     not qualify for <font color="blue">FEMA GRAS </font>de<font color="blue">termination</font>, we will be required to pursue a     lengthy  FDA  approval  process or dedicate our <font color="blue">development</font> efforts to     <font color="blue">alternative</font> compounds, which would further delay <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In     addition,  laws,  <font color="blue">regulations</font> or FDA <font color="blue">practice governing</font> the <font color="blue">regulatory</font>     <font color="blue">approval process</font>, the <font color="blue">availability</font> of the GRAS de<font color="blue">termination</font> process or the     <font color="blue">manufacture</font> or labeling of such products, may change in a manner that could     <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue">commercialize</font> products on schedule or at     all</td>
    </tr>
    <tr>
      <td>Sales of our flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> outside of the     <font color="blue">United States </font>will be subject to foreign <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In most     cases,  whether  or  not a GRAS de<font color="blue">termination</font> or FDA approval has been     obtained, approval of a product by the comparable <font color="blue">regulatory</font> authorities of     <font color="blue">foreign countries must still</font> be obtained prior to <font color="blue">manufacturing</font> or marketing     the product in those countries</td>
    </tr>
    <tr>
      <td>A GRAS de<font color="blue">termination</font> or FDA approval in the     <font color="blue">United States </font>or in any other <font color="blue">jurisdiction</font> does not <font color="blue">ensure approval</font> in other     <font color="blue">jurisdiction</font>s because the <font color="blue">requirements</font> from <font color="blue">jurisdiction</font> to <font color="blue">jurisdiction</font> may     <font color="blue">vary widely</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>foreign approvals could result in <font color="blue"><font color="blue">significant</font> delays</font>,     <font color="blue"><font color="blue">difficult</font>ies</font> and costs for us and require <font color="blue">additional <font color="blue">safety studies</font></font> and     <font color="blue">additional expenses</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> these <font color="blue">regulatory</font> <font color="blue">requirements</font>     or  to obtain and maintain required approvals, our ability to generate     <font color="blue">revenue will</font> be diminished</td>
    </tr>
    <tr>
      <td>We  and  our  <font color="blue"><font color="blue">collaborator</font>s</font>  may not be successful in overcoming these     <font color="blue">regulatory</font>  hurdles,  which  could  result  in  product launch delays,     <font color="blue">unanticipated</font> expenses, <font color="blue">termination</font> of <font color="blue"><font color="blue">collaboration</font>s</font>, and flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> not being approved for <font color="blue">incorporation</font> into     <font color="blue">consumer products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">consequences would</font> have a material adverse effect     on our business <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________         Even if we or our <font color="blue"><font color="blue">collaborator</font>s</font> receive a GRAS de<font color="blue">termination</font> or <font color="blue">regulatory</font>     approval and <font color="blue">incorporate</font> our flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font>     <font color="blue">into products</font>, those <font color="blue"><font color="blue">products may</font> never</font> be <font color="blue">commercially successful</font></td>
    </tr>
    <tr>
      <td>Even  if  we  discover and develop flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font>  that obtain the <font color="blue">necessary</font> GRAS de<font color="blue">termination</font> or <font color="blue">regulatory</font>     approval, our <font color="blue">success depends</font> to a <font color="blue"><font color="blue">significant</font> degree upon</font> the commercial     success of <font color="blue">packaged food</font> and <font color="blue">beverage products</font> <font color="blue">incorporating</font> those flavors,     flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>If these products fail to achieve or     <font color="blue">subsequently</font>  maintain  <font color="blue">market <font color="blue">acceptance</font></font> or <font color="blue">commercial viability</font>, our     business  would be <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> harmed</font> because our <font color="blue">royalty revenue</font> is     <font color="blue">dependent upon consumer sales</font> of these products</td>
    </tr>
    <tr>
      <td>In addition, we could be     unable  to maintain our existing <font color="blue"><font color="blue">collaboration</font>s</font> or <font color="blue">attract new product</font>     <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors may affect</font> the market     <font color="blue">acceptance</font> and <font color="blue">commercial success</font> of any <font color="blue">potential products</font> <font color="blue">incorporating</font>     flavors,  flavor  <font color="blue">enhancers</font>  or taste <font color="blue">modulators</font> that we <font color="blue">may discover</font>,     including:         •                   health  concerns,  <font color="blue">whether actual</font> or perceived, or     <font color="blue">unfavorable publicity</font> regarding our flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font> or those of our <font color="blue">competitors</font>;       •                  the timing of <font color="blue">market entry as compared</font> to <font color="blue">competitive</font>     products;       •                  the rate of adoption of <font color="blue">products by</font> our <font color="blue"><font color="blue">collaborator</font>s</font> and     other companies in the <font color="blue">flavor industry</font>; and       •                  any <font color="blue">product labeling</font> that may be required by the FDA or     other  United  States  or  foreign  <font color="blue">regulatory</font>  agencies  for products     <font color="blue">incorporating</font> our flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>We have a history of operating losses and we may not achieve or maintain     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">been profitable</font> and have generated substantial operating losses     since we were <font color="blue">incorporate</font>d in <font color="blue">September </font>1998</td>
    </tr>
    <tr>
      <td>We <font color="blue">incurred net losses</font> of     approximately dlra19dtta8 million for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of approximately dlra104dtta2     million</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur additional losses</font> for at least the next two     years</td>
    </tr>
    <tr>
      <td>The extent of our future losses will depend, in part, on the rate of     increase in our operating expenses and the rate of growth, if any, in our     revenue  from  our  <font color="blue">five existing</font> and any future <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font> as well as from other sources that may become     available to us in the future and on the level of our expenses</td>
    </tr>
    <tr>
      <td>To date, our     revenue has <font color="blue">come solely from research</font> and <font color="blue">development</font> funding, upfront fees,     <font color="blue">cost reimbursement</font> and <font color="blue">milestone payments</font> under our <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font>s with</font> Cadbury Schweppes, Campbell Soup,     Coca-Cola, <font color="blue">Kraft Foods </font>and Nestle</td>
    </tr>
    <tr>
      <td>In order for us to <font color="blue">generate royalty</font>     revenue and <font color="blue">become profitable</font>, we must retain our existing <font color="blue">product <font color="blue">discovery</font></font>     and <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font> and our <font color="blue"><font color="blue">collaborator</font>s</font> must <font color="blue">commercialize</font>     products <font color="blue">incorporating</font> one or more of our flavors, flavor <font color="blue">enhancers</font> or taste     <font color="blue">modulators</font>,  from which we can derive <font color="blue">royalty revenue</font>s</td>
    </tr>
    <tr>
      <td>Our ability to     generate <font color="blue">royalty revenue</font> is uncertain and <font color="blue">will depend upon</font> our ability to     meet particular research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We expect that our results of <font color="blue">operations</font> will fluctuate from period to     period, and this <font color="blue">fluctuation could</font> cause our stock price to decline, causing     <font color="blue">investor losses</font></td>
    </tr>
    <tr>
      <td>Our operating results have fluctuated in the past and are likely to vary     <font color="blue"><font color="blue">significant</font>ly</font> in the <font color="blue">future based upon</font> a number of factors, many of which we     have little or no <font color="blue">control over</font></td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">highly dynamic industry</font> and     future  results  could  be  subject to <font color="blue"><font color="blue">significant</font> <font color="blue">fluctuations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">fluctuations</font> could</font> cause us to fail to meet or <font color="blue">exceed financial expectations</font>     of <font color="blue">securities analysts</font> or investors, <font color="blue">which could</font> cause our stock price to     <font color="blue">decline rapidly</font> and <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>Revenue and expenses in future periods     may  be  greater  or less than revenue and expenses in the <font color="blue">immediately</font>     <font color="blue">preceding period</font> or in the <font color="blue">comparable period</font> of the prior year</td>
    </tr>
    <tr>
      <td>Therefore,     period-to-period comparisons of our operating results are not <font color="blue">necessarily</font> a     good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Some of the factors that could     cause our operating results to fluctuate include:         •                   <font color="blue">termination</font>  of  any  of our <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue">collaboration</font> <font color="blue">agreement</font>s;                                           27     ______________________________________________________________________         •                  our ability to discover and develop flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> or the ability of our <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font>  <font color="blue"><font color="blue">collaborator</font>s</font>  to <font color="blue">incorporate</font> them into <font color="blue">packaged food</font> and     <font color="blue">beverage products</font>;       •                  our receipt of <font color="blue">milestone payments</font> in any particular     period;       •                   the  ability  and  <font color="blue">willingness</font> of <font color="blue"><font color="blue">collaborator</font>s</font> to     <font color="blue">commercialize</font> products <font color="blue">incorporating</font> our flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font> on expected timelines, or at all;       •                  our ability to <font color="blue">enter into</font> new <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font> and <font color="blue">technology</font> <font color="blue"><font color="blue">collaboration</font>s</font> or to extend the     terms of our existing <font color="blue">collaboration</font> <font color="blue">agreement</font>s and our <font color="blue">payment obligations</font>,     expected revenue and other terms of any other <font color="blue">agreement</font>s of this type;       •                   our  ability,  or  our  <font color="blue"><font color="blue">collaborator</font>s</font>’ ability, to     <font color="blue"><font color="blue">successfully</font> satisfy</font> all pertinent <font color="blue">regulatory</font> <font color="blue">requirements</font>;       •                  the demand for our <font color="blue"><font color="blue">collaborator</font>s</font>’ <font color="blue">products containing</font> our     flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font>; and       •                  general and industry specific economic conditions, which     may affect our <font color="blue"><font color="blue">collaborator</font>s</font>’ research and <font color="blue">development</font> expenditures</td>
    </tr>
    <tr>
      <td>Changes in financial <font color="blue">accounting</font> standards related to stock option expenses     are expected to have a <font color="blue">significant</font> effect on our reported results</td>
    </tr>
    <tr>
      <td>The FASB <font color="blue">recently issued</font> a revised standard that requires that we record     <font color="blue">compensation expense</font> in the statement of <font color="blue">operations</font> for <font color="blue">employee stock</font>     <font color="blue">options using</font> the <font color="blue">fair value method</font></td>
    </tr>
    <tr>
      <td>The adoption of the new standard is     expected to have a <font color="blue">significant</font> effect on our reported earnings, although it     will not affect our <font color="blue">cash flows</font>, and <font color="blue">could <font color="blue">adversely</font> impact</font> our ability to     provide accurate <font color="blue">guidance on</font> our projected <font color="blue">future financial</font> results due to     the <font color="blue">variability</font> of the <font color="blue">factors used</font> to establish the value of <font color="blue">stock options</font></td>
    </tr>
    <tr>
      <td>As a result, the adoption of the new standard in the <font color="blue">first quarter</font> of fiscal     2006 could <font color="blue">negatively</font> affect our stock price and our <font color="blue">stock price volatility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with regulation</font> of <font color="blue">corporate governance</font> and <font color="blue">public <font color="blue">disclosure</font> may</font>     result in <font color="blue">additional expenses</font></td>
    </tr>
    <tr>
      <td>Laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font> and public     <font color="blue">disclosure</font>, including the Sarbanes-Oxley Act of 2002, SEC <font color="blue">regulations</font> and     <font color="blue">Nasdaq National Market </font>rules, is costly</td>
    </tr>
    <tr>
      <td>Our efforts to <font color="blue">comply with</font> these     laws, <font color="blue">regulations</font> and standards, as they <font color="blue">become applicable</font> to us, have     resulted  in,  and  are  likely  to continue to result in, general and     <font color="blue">administrative expense</font> and <font color="blue">management</font> time related to <font color="blue">compliance activities</font></td>
    </tr>
    <tr>
      <td>In particular, our efforts to <font color="blue">comply with</font> Section 404 of the Sarbanes-Oxley     Act of 2002 and the related <font color="blue">regulations</font> regarding our required <font color="blue">assessment</font> of     our <font color="blue">internal controls over financial</font> reporting and our <font color="blue">external auditors</font>’     audit of that <font color="blue">assessment</font> requires the <font color="blue">commitment</font> of <font color="blue">significant</font> financial     and <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>If our efforts to <font color="blue">comply with</font> laws, <font color="blue">regulations</font>     and <font color="blue">standards differ from</font> the activities intended by <font color="blue">regulatory</font> or governing     bodies, our <font color="blue">reputation may</font> be harmed and we might be subject to sanctions or     investigation by <font color="blue">regulatory</font> authorities, such as the Securities and Exchange     Commission</td>
    </tr>
    <tr>
      <td>Any such action could <font color="blue"><font color="blue">adversely</font> affect</font> our financial results and     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may need to obtain <font color="blue">additional capital</font> to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> <font color="blue">commercialize</font> our flavors, flavor <font color="blue">enhancers</font>     and taste <font color="blue">modulators</font>, we may need to obtain <font color="blue">additional capital</font> or change our     strategy  to  continue  our  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, our business and     <font color="blue">operations</font> may change in a manner that <font color="blue">would consume available resources at</font>     a  greater  rate than anticipated</td>
    </tr>
    <tr>
      <td>In such event, we may need to raise     substantial <font color="blue">additional capital</font> to, among other things:         •                  fund new research, <font color="blue">discovery</font> or <font color="blue">development</font> programs;       •                  advance additional <font color="blue">product <font color="blue">candidates</font></font> into and through     the <font color="blue"><font color="blue">regulatory</font> approval</font> process; and       •                   acquire  rights to products or <font color="blue">product <font color="blue">candidates</font></font>,     <font color="blue">technologies</font> or <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________         If we require <font color="blue">additional capital</font> to continue our <font color="blue">operations</font>, we cannot     assure you that <font color="blue">additional financing will</font> be <font color="blue">available on terms</font> acceptable     to us, or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available or are not available     on acceptable terms, our ability to fund our <font color="blue">operations</font>, take advantage of     <font color="blue">opportunities</font>, identify and develop flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font>,  develop  <font color="blue">technologies</font> or otherwise respond to <font color="blue">competitive</font>     <font color="blue">pressures could</font> be <font color="blue"><font color="blue">significant</font>ly</font> limited</td>
    </tr>
    <tr>
      <td>In addition, if financing is not     available,  we  may need to alter our strategy or cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     addition, issuances of debt or <font color="blue">additional equity could impact</font> the rights of     the holders of our <font color="blue">common stock</font>, may dilute our <font color="blue">stockholders</font>’ ownership and     <font color="blue">may impose restrictions on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">restrictions could</font> include     limitations on additional borrowing, specific restrictions on the use of our     assets  as  well  as  <font color="blue">prohibitions on</font> our ability to create liens, pay     dividends, redeem our stock or make <font color="blue">investments</font></td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">key personnel</font> or are unable to attract and retain qualified     personnel, it could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue"><font color="blue">significant</font> degree upon</font> the <font color="blue">continued contributions</font>     of our executive officers, <font color="blue">management</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>If we lose the     services of one or more of these people and, in particular, Kent Snyder, our     President and Chief Executive Officer, or Mark Zoller, Ph</td>
    </tr>
    <tr>
      <td>D, our Executive     Vice President of Discovery &amp; Development and Chief Scientific Officer, the     <font color="blue"><font color="blue">relationship</font>s</font> we have with our <font color="blue"><font color="blue">collaborator</font>s</font> would likely be <font color="blue">negatively</font>     impacted and we may be delayed or unable to develop new <font color="blue">product <font color="blue">candidates</font></font>,     <font color="blue">commercialize</font> our existing <font color="blue">product <font color="blue">candidates</font></font> or achieve our other business     <font color="blue">objectives</font>, any of <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We have     entered into <font color="blue">employment</font> letter <font color="blue">agreement</font>s with the <font color="blue">following executive</font>     officers: Kent Snyder, Mark Zoller, Ph</td>
    </tr>
    <tr>
      <td>D, our Vice President, Discovery</td>
    </tr>
    <tr>
      <td>All of our employees are     at-will employees, which means that either we or the employee <font color="blue">may terminate</font>     their <font color="blue"><font color="blue">employment</font> at</font> any time</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">discovery</font> and <font color="blue">development</font> programs <font color="blue">depend on</font> our ability to     attract  and  retain  highly  skilled  <font color="blue">scientists</font>, including molecular     biologists, biochemists, chemists and engineers</td>
    </tr>
    <tr>
      <td>We may not be able to     attract or retain <font color="blue">qualified employees</font> in the future due to the intense     <font color="blue">competition</font> for qualified personnel among <font color="blue">technology</font>-based <font color="blue">businesses</font>,     <font color="blue">particularly</font>  in  the  San  Diego  area</td>
    </tr>
    <tr>
      <td>We also face <font color="blue">competition</font> from     <font color="blue">universities</font> and public and <font color="blue">private research <font color="blue">institutions</font></font> in recruiting and     retaining <font color="blue">highly qualified scientific</font> and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>If we are     not able to attract and retain the <font color="blue">necessary</font> personnel to accomplish our     business <font color="blue">objectives</font>, we may experience <font color="blue">constraints</font> that <font color="blue">will <font color="blue">adversely</font></font>     affect our ability to meet the demands of our current or any <font color="blue">future product</font>     <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> in a <font color="blue">timely fashion</font> or to support     our independent <font color="blue">discovery</font> and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> managing our growth, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>Our strategy includes <font color="blue">entering into</font> and working <font color="blue">on simultaneous flavor</font> and     <font color="blue">flavor enhancer</font> <font color="blue">discovery</font> and <font color="blue">development</font> programs across multiple markets</td>
    </tr>
    <tr>
      <td>We  increased  the  number  of  our  full-time employees from seven on     <font color="blue">December </font>31, 1999 to 90 on <font color="blue">December </font>31, 2005 and we expect to continue to     grow to meet our strategic <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">growth continues</font>, it will     continue to place a strain on us, our <font color="blue">management</font> and our resources</td>
    </tr>
    <tr>
      <td>Our     ability to <font color="blue">effectively manage</font> our <font color="blue">operations</font>, growth and various projects     requires us to continue to improve our operational, financial and <font color="blue">management</font>     controls,  reporting  systems and procedures and to attract and retain     <font color="blue">sufficient numbers</font> of <font color="blue">talented employees</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font>     implement these tasks on a <font color="blue">larger scale</font> and, <font color="blue">accordingly</font>, we may not achieve     our research, <font color="blue">development</font> and <font color="blue">commercialization</font> goals</td>
    </tr>
    <tr>
      <td>If we fail to improve     our operational, financial and <font color="blue">management</font> information systems, or fail to     <font color="blue">effectively monitor</font> or manage our new and <font color="blue">future employees</font> or our growth,     our business would suffer <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>In addition, no assurance can be     made that we will be able to <font color="blue">secure adequate <font color="blue">facilities</font></font> to house our staff,     conduct our research or achieve our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________         We <font color="blue">will rely on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> our flavors, flavor <font color="blue">enhancers</font>     and taste <font color="blue">modulators</font> on a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>We do not have experience in <font color="blue">manufacturing</font>, nor do we have the resources or     <font color="blue">facilities</font> to <font color="blue">manufacture</font>, flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> on     a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>Therefore, the <font color="blue">commercialization</font> of our flavors, flavor     <font color="blue">enhancers</font>  and  taste  <font color="blue">modulators</font>  will  depend  in part on our or our     <font color="blue"><font color="blue">collaborator</font>s</font>’ ability to contract with third-party <font color="blue">manufacture</font>rs of our     flavors,  flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> on a large scale, at a     <font color="blue">competitive</font> cost, with the specified quality and in <font color="blue">accordance with relevant</font>     food  and  beverage  <font color="blue">regulatory</font>  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Any  such  third-party     <font color="blue">manufacture</font>rs may encounter <font color="blue">manufacturing</font> <font color="blue"><font color="blue">difficult</font>ies</font> at any time that     could result in delays in the <font color="blue">commercialization</font> of potential flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to find capable third-party     <font color="blue">manufacture</font>rs  or  to  enter  into <font color="blue">agreement</font>s on acceptable terms with     third-party <font color="blue">manufacture</font>rs <font color="blue">could delay</font> <font color="blue">commercialization</font> of any products we     may develop and may harm our <font color="blue"><font color="blue">relationship</font>s</font> with our existing and any future     <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> and our customers</td>
    </tr>
    <tr>
      <td>Moreover,     if we are required to change from one third-party <font color="blue">manufacture</font>r to another     for  any  reason, the <font color="blue">commercialization</font> of our <font color="blue">products may</font> be delayed     further</td>
    </tr>
    <tr>
      <td>In addition, if third-party <font color="blue">manufacture</font>rs fail to <font color="blue">comply with</font> the     FDA’s good <font color="blue">manufacturing</font> practice <font color="blue">regulations</font> or similar <font color="blue">regulations</font> in     other  countries,  then we may be subject to adverse <font color="blue">regulatory</font> action     including product recalls, warning letters and withdrawal of our products,     or our <font color="blue"><font color="blue">collaborator</font>s</font>’ or customers’ products, from the market</td>
    </tr>
    <tr>
      <td>Further, because our flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> are     <font color="blue">regulated as food products under</font> the Federal Food, Drug and Cosmetic Act, we     and the <font color="blue"><font color="blue">third parties</font> with which</font> we <font color="blue">collaborate</font> or contract to <font color="blue">manufacture</font>,     process,  pack, import or otherwise handle our products or our product     ingredients, may be required to <font color="blue">comply with</font> certain registration, prior     notice submission, recordkeeping and other <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>of any party in the chain of <font color="blue">distribution</font> to <font color="blue">comply with</font> any applicable     <font color="blue">requirements</font> under the Federal Food, Drug and Cosmetic Act or the FDA’s     <font color="blue">implementing</font>  <font color="blue">regulations</font>,  or similar <font color="blue">regulations</font> in other countries,     may <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">manufacture</font> and/or <font color="blue">distribution</font> of our products in     commerce</td>
    </tr>
    <tr>
      <td>If we acquire products, <font color="blue">technologies</font> or other <font color="blue">businesses</font>, we will incur a     variety of costs, may have integration <font color="blue"><font color="blue">difficult</font>ies</font> and may experience     numerous other risks that could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>If appropriate <font color="blue">opportunities</font> become available, we may consider acquiring     <font color="blue">businesses</font>, <font color="blue">technologies</font> or products that we believe are a <font color="blue">strategic fit</font>     with our business</td>
    </tr>
    <tr>
      <td>We currently have no <font color="blue">commitment</font>s or <font color="blue">agreement</font>s with     respect to, and are not <font color="blue">actively seeking</font>, any material <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We have     limited  experience  in  identifying <font color="blue">acquisition</font> targets, <font color="blue">successfully</font>     acquiring them and <font color="blue">integrating them into</font> our <font color="blue">current infrastructure</font></td>
    </tr>
    <tr>
      <td>We     may not  be  able  to <font color="blue">successfully</font> integrate any <font color="blue">businesses</font>, products,     <font color="blue">technologies</font> or personnel that we might acquire in the <font color="blue">future without</font> a     <font color="blue">significant</font> expenditure of operating, financial and <font color="blue">management</font> resources, if     at all</td>
    </tr>
    <tr>
      <td>In addition, future <font color="blue"><font color="blue">acquisition</font>s</font> might be <font color="blue">funded by issuances</font> of     <font color="blue">additional debt</font> or equity, <font color="blue">which could</font> impact your rights as a holder of our     <font color="blue">common stock</font> and may dilute your <font color="blue">ownership percentage</font></td>
    </tr>
    <tr>
      <td>Any of the foregoing     could have a <font color="blue">significant</font> adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks Related To Our Industry         Our ability to compete in the flavor and <font color="blue">flavor enhancer</font> market may decline     if we do not <font color="blue">adequately protect</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our  success  depends  in  part on  our ability to obtain and maintain     <font color="blue"><font color="blue">intellectual</font> property</font> that protects our <font color="blue">technologies</font> and flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">positions may</font> be <font color="blue">highly uncertain</font> and     <font color="blue">may involve complex legal</font> and factual questions, including the ability to     <font color="blue">establish <font color="blue">patentability</font></font> of sequences relating to taste <font color="blue">receptors</font>, proteins,     chemical synthesis <font color="blue">techniques</font>, compounds and methods for using them to     modulate taste for which we <font color="blue">seek <font color="blue">patent protection</font></font></td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent</font> standard     regarding  the <font color="blue">allowability</font> or <font color="blue">enforceability</font> of claims in many of our     pending patent <font color="blue">application</font>s has                                           30     ______________________________________________________________________         emerged to date</td>
    </tr>
    <tr>
      <td>As a result, we cannot predict the breadth of claims that     will ultimately be allowed in our patent <font color="blue">application</font>s, if any, including     those we have in-licensed or the extent to which we may enforce these claims     against our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">future protection</font> for our <font color="blue">proprietary</font>     rights is therefore <font color="blue">highly uncertain</font> and we <font color="blue">cannot assure</font> you that:         •                  we were the first to file patent <font color="blue">application</font>s or to     invent the subject matter claimed in patent <font color="blue">application</font>s relating to the     <font color="blue">technologies</font> upon which we rely;       •                   others  will  not <font color="blue">independently</font> develop similar or     <font color="blue">alternative</font> <font color="blue">technologies</font> or duplicate any of our <font color="blue">technologies</font>;       •                  others did not publicly disclose our claimed <font color="blue">technology</font>     before  we  conceived the subject matter included in any of our patent     <font color="blue">application</font>s;       •                  any of our patent <font color="blue">application</font>s will result in issued     patents;       •                   any  of our patent <font color="blue">application</font>s will not result in     <font color="blue">interferences</font>  or  disputes  with  <font color="blue">third parties</font> regarding priority of     invention;       •                  any patents that have issued or may be issued to us, our     <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue"><font color="blue">licensors</font> will provide</font> a basis for <font color="blue">commercially viable</font>     products or <font color="blue">will provide us with</font> any <font color="blue">competitive</font> advantages or will not be     challenged by <font color="blue">third parties</font>;       •                  we will develop additional <font color="blue">proprietary</font> <font color="blue">technologies</font> that     are patentable;       •                  the patents of <font color="blue">others will</font> not have an adverse effect on     our ability to do business; or       •                   new  <font color="blue">proprietary</font>  <font color="blue">technologies</font> from <font color="blue">third parties</font>,     including existing <font color="blue">licensors</font>, will be available for licensing to us on     <font color="blue">reasonable commercial terms</font>, if at all</td>
    </tr>
    <tr>
      <td>In addition, patent law outside the <font color="blue">United States </font>is uncertain and in many     countries <font color="blue"><font color="blue">intellectual</font> property</font> laws are <font color="blue">undergoing review</font> and revision</td>
    </tr>
    <tr>
      <td>The     laws of some countries do not protect <font color="blue"><font color="blue">intellectual</font> property</font> rights to the     same  <font color="blue">extent as domestic laws</font></td>
    </tr>
    <tr>
      <td>It may be <font color="blue">necessary</font> or useful for us to     <font color="blue">participate</font> in <font color="blue">opposition <font color="blue">proceedings</font></font> to determine the validity of our     <font color="blue">competitors</font>’  patents  or  to defend the validity of any of our or our     licensor’s future patents, <font color="blue">which could</font> result in substantial costs and would     divert our efforts and <font color="blue">attention from</font> other aspects of our business</td>
    </tr>
    <tr>
      <td><font color="blue">Technologies </font>licensed to <font color="blue">us by others</font>, or in-licensed <font color="blue">technologies</font>, are     important to our business</td>
    </tr>
    <tr>
      <td>In particular, we <font color="blue">depend on</font> high-throughput     screening <font color="blue">technologies</font> that we licensed from Aurora Biosciences, <font color="blue">technology</font>     related  to  certain taste <font color="blue"><font color="blue">receptor sequence</font>s</font> that we <font color="blue">license from</font> the     <font color="blue">University of California </font>and others and <font color="blue">technology</font> related to compound     libraries that we <font color="blue">license from</font> <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, we may in the     future acquire rights to additional <font color="blue">technologies</font> by licensing such rights     <font color="blue">from existing <font color="blue">licensors</font></font> or from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Also,  we  <font color="blue">generally</font>  do  not control the <font color="blue">patent prosecution</font>,     maintenance or <font color="blue">enforcement</font> of in-licensed <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are     unable  to  exercise the same degree of <font color="blue">control over</font> this <font color="blue">intellectual</font>     <font color="blue">property as</font> we do over our <font color="blue">internally</font> developed <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Moreover, some     of our academic institution <font color="blue">licensors</font>, <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">scientific advisors</font>     have rights to <font color="blue">publish data</font> and information to which we have rights</td>
    </tr>
    <tr>
      <td>If we     cannot  maintain  the  <font color="blue">confidential</font>ity  of  our <font color="blue">technologies</font> and other     <font color="blue">confidential</font> information in <font color="blue">connection with</font> our <font color="blue"><font color="blue">collaboration</font>s</font>, our ability     to protect our <font color="blue">proprietary</font> information or obtain <font color="blue">patent protection</font> in the     <font color="blue">future may</font> be impaired, <font color="blue">which could</font> have a <font color="blue">significant</font> adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Many of the patent <font color="blue">application</font>s we and our <font color="blue">licensors</font> have filed have not yet     <font color="blue">been <font color="blue">substantively</font></font> examined and may not result in patents being issued</td>
    </tr>
    <tr>
      <td>Many of the patent <font color="blue">application</font>s filed by us and our <font color="blue">licensors</font> were filed     <font color="blue">recently with</font> the <font color="blue">United States </font>Patent and Trademark Office and most have     not <font color="blue">been <font color="blue">substantively</font></font> examined and may not result in patents being issued</td>
    </tr>
    <tr>
      <td>Some of these patent <font color="blue">application</font>s claim sequences that were identified from     <font color="blue">different</font>  publicly available sequence information sources such as the     High-Throughput Genomic Sequences division of GenBank</td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font> to     predict whether any of our or our <font color="blue">licensors</font>’ <font color="blue">application</font>s will ultimately be     found  to be patentable or, if so, to predict the scope of any allowed     claims</td>
    </tr>
    <tr>
      <td>In  addition,  the <font color="blue">disclosure</font> in our or our <font color="blue">licensors</font>’ patent     <font color="blue">application</font>s,  <font color="blue">particularly</font>  in  respect of the utility of our claimed     <font color="blue">inventions</font>, may not be sufficient to meet the statutory <font color="blue">requirements</font> for     <font color="blue">patentability</font> in all cases</td>
    </tr>
    <tr>
      <td>As a result, it is <font color="blue">difficult</font> to predict whether     any of our or our <font color="blue">licensors</font>’ <font color="blue">application</font>s will be allowed, or, if so, to     predict the scope of                                           31     ______________________________________________________________________         any  allowed  claims  or  the  <font color="blue">enforceability</font>  of the patents</td>
    </tr>
    <tr>
      <td>Even if     enforceable, others may be able to <font color="blue">design around</font> any patents or develop     similar <font color="blue">technologies</font> that are not within the scope of <font color="blue">such patents</font></td>
    </tr>
    <tr>
      <td>Our and     our  <font color="blue">licensors</font>’ patent <font color="blue">application</font>s may not issue as patents that will     provide us with any protection or <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>Disputes <font color="blue">concerning</font> the <font color="blue">infringement</font> or <font color="blue">misappropriation</font> of our <font color="blue">proprietary</font>     rights or the <font color="blue">proprietary</font> rights of <font color="blue">others could</font> be time consuming and     <font color="blue">extremely costly</font> and <font color="blue">could delay</font> our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font>, if any, will be <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> harmed</font> if we infringe     the <font color="blue">patent rights</font> of <font color="blue">third parties</font> or if we breach any license or other     <font color="blue">agreement</font>s  that we have <font color="blue">entered into with</font> regard to our <font color="blue">technology</font> or     business</td>
    </tr>
    <tr>
      <td>We are aware of other companies and <font color="blue">academic <font color="blue">institutions</font></font> that have been     performing research in the areas of taste modulation and flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>In particular, other companies and academic     <font color="blue">institutions</font> have announced that they have conducted taste-<font color="blue">receptor research</font>     and have <font color="blue">published data on</font> taste <font color="blue">receptor sequence</font> information and taste     <font color="blue">receptors</font> or filed patent <font color="blue">application</font>s or obtained <font color="blue">patent protection</font> on     taste modulation or taste <font color="blue">receptors</font> and their uses, including Linguagen     Corp, Mount Sinai School of Medicine, The Scripps Research Institute, the     <font color="blue">University  </font>of California, Monell Chemical Senses Corp, Pfizer, Inc,     Virginia  Commonwealth  <font color="blue">University  </font>and  the German Institute of Human     Nutrition</td>
    </tr>
    <tr>
      <td>To the extent any of these companies or <font color="blue">academic <font color="blue">institutions</font></font>     currently have, or obtain in the future, broad patent claims, <font color="blue">such patents</font>     could  block  our  ability to <font color="blue">use various aspects</font> of our <font color="blue">discovery</font> and     <font color="blue">development</font> process and <font color="blue">might prevent us from</font> developing or <font color="blue">commercializing</font>     newly discovered flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> or otherwise     conducting our business</td>
    </tr>
    <tr>
      <td>The University of California, for example, claims     certain <font color="blue">patent rights</font> relating to the <font color="blue">coexpression</font> of T1R <font color="blue">receptors</font> that     may not have <font color="blue">been licensed</font> to us</td>
    </tr>
    <tr>
      <td>While our <font color="blue">technology</font> is <font color="blue">focused on</font> the use     of human T1R <font color="blue">receptors</font>, we <font color="blue">cannot assure</font> you that it does not <font color="blue">infringe such</font>     <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>In such event, if we are not able to amend our <font color="blue">license with</font>     the  <font color="blue">University  </font>of  <font color="blue">California  </font>to include such <font color="blue">patent rights</font> and our     <font color="blue">technology</font> is found to interfere with or <font color="blue">infringe such</font> <font color="blue">patent rights</font>, our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could suffer a     <font color="blue">significant</font> adverse effect</td>
    </tr>
    <tr>
      <td>In addition, it is possible that some of the     flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> that are <font color="blue">discovered using</font> our     <font color="blue">technology</font> may not be patentable or may be covered by <font color="blue"><font color="blue">intellectual</font> property</font>     of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We are not currently a party to any <font color="blue">litigation</font>, interference, opposition,     protest,  <font color="blue">reexamination</font>,  reissue  or  any  other  <font color="blue"><font color="blue">potentially</font> adverse</font>     governmental, ex parte or inter-party proceeding with regard to our patent     or <font color="blue">trademark positions</font></td>
    </tr>
    <tr>
      <td>However, the <font color="blue">life sciences</font> and other <font color="blue">technology</font>     <font color="blue">industries</font> are <font color="blue">characterized by</font> extensive <font color="blue">litigation</font> regarding patents and     other <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>Many <font color="blue">life sciences</font> and other <font color="blue">technology</font>     companies have employed <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> as a way to gain a     <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>If we become involved in <font color="blue">litigation</font>, interference     <font color="blue">proceedings</font>,  oppositions, <font color="blue">reexamination</font>, protest or other <font color="blue">potentially</font>     adverse  <font color="blue">intellectual</font>  property  <font color="blue">proceedings</font>  as  a  result of alleged     <font color="blue">infringement</font> by us of the rights of others or as a result of priority of     invention disputes with <font color="blue">third parties</font>, we might have to spend <font color="blue">significant</font>     amounts of money, time and <font color="blue">effort defending</font> our position and we may not be     successful</td>
    </tr>
    <tr>
      <td>In  addition,  any claims relating to the <font color="blue">infringement</font> of     third-party <font color="blue">proprietary</font> rights or <font color="blue">proprietary</font> de<font color="blue">termination</font>s, even if not     <font color="blue">meritorious</font>,  could  result in costly <font color="blue">litigation</font>, lengthy governmental     <font color="blue">proceedings</font>, divert <font color="blue">management</font>’s attention and resources, or require us to     <font color="blue">enter into</font> royalty or license <font color="blue">agreement</font>s that are not <font color="blue">advantageous</font> to us</td>
    </tr>
    <tr>
      <td>Should any person have filed patent <font color="blue">application</font>s or obtained patents that     claim  <font color="blue">inventions</font> also claimed by us, we may have to <font color="blue">participate</font> in an     <font color="blue">interference proceeding</font> declared by the relevant patent <font color="blue">regulatory</font> agency to     determine priority of invention and, thus, the right to a patent for these     <font color="blue">inventions</font>  in  the  United  States</td>
    </tr>
    <tr>
      <td>Even if successful     on priority grounds, an <font color="blue">interference action</font> may result in loss of claims     based  on  <font color="blue">patentability</font>  grounds  raised  in the <font color="blue">interference action</font></td>
    </tr>
    <tr>
      <td>Litigation, interference <font color="blue">proceedings</font> or other <font color="blue">proceedings</font> could divert     <font color="blue">management</font>’s time and efforts</td>
    </tr>
    <tr>
      <td>Even <font color="blue">unsuccessful</font> claims could result in     <font color="blue">significant</font> legal fees and other expenses, diversion of <font color="blue">management</font>’s time     and <font color="blue">disruption</font> in our business</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting <font color="blue">from initiation</font> and     <font color="blue">continuation</font> of any <font color="blue">patent proceeding</font> or related <font color="blue">litigation</font> could                                           32     ______________________________________________________________________         harm our ability to compete and could have a <font color="blue">significant</font> adverse effect on     our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>An  adverse  ruling  arising out of any <font color="blue"><font color="blue">intellectual</font> property</font> dispute,     including an <font color="blue">adverse decision as</font> to the priority of our <font color="blue">inventions</font>, could     undercut or invalidate our <font color="blue"><font color="blue">intellectual</font> property</font> position</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse ruling</font>     could  also subject us to <font color="blue">significant</font> <font color="blue">liability</font> for damages, including     possible treble damages, prevent us from using <font color="blue">technologies</font> or developing     products, or require us to <font color="blue">negotiate licenses</font> to <font color="blue">disputed rights from third</font>     parties</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>patent  and  <font color="blue"><font color="blue">intellectual</font> property</font> disputes in the     <font color="blue">technology</font> area are <font color="blue">often settled through licensing</font> or similar <font color="blue">arrangements</font>,     costs  <font color="blue">associated with</font> these <font color="blue">arrangements</font> may be substantial and could     include <font color="blue">license fees</font> and <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">necessary</font> licenses     may not be available to us on satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>Failure to     obtain a license in such a case could have a <font color="blue">significant</font> adverse effect on     our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable to protect our <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font>     information, we <font color="blue">could lose</font> any <font color="blue">competitive</font> advantage we may have, which     could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We  rely  in  part <font color="blue">on trade secret protection</font> for our <font color="blue">confidential</font> and     <font color="blue">proprietary</font> information, know how and processes</td>
    </tr>
    <tr>
      <td>Our policy is to execute     <font color="blue">proprietary</font> information and invention <font color="blue">agreement</font>s with our employees and     <font color="blue">consultants</font>  upon  the  <font color="blue">commencement</font>  of  an  <font color="blue">employment</font> or consulting     <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s <font color="blue">generally</font> require that all <font color="blue">confidential</font>     information developed by the individual or made known to the individual by     us  during the course of the individual’s <font color="blue"><font color="blue">relationship</font> with</font> us be kept     <font color="blue">confidential</font> and not be disclosed to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s also     <font color="blue">generally</font> provide that <font color="blue">inventions</font> conceived by the individual in the course     of  their  <font color="blue">employment</font> shall be our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will be able to <font color="blue">effectively enforce</font> these <font color="blue">agreement</font>s or     that <font color="blue">proprietary</font> information is our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that the subject <font color="blue">proprietary</font> information will not be disclosed,     that  others  will  not <font color="blue">independently</font> develop <font color="blue">substantially</font> equivalent     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our trade     secrets or that we can <font color="blue">meaningfully protect</font> our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Costly and     time-consuming <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and determine the     scope of our <font color="blue">proprietary</font> rights, and failure to obtain or maintain trade     secret protection could <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">competitive</font> business position</td>
    </tr>
    <tr>
      <td>Many potential <font color="blue">competitors</font>, including those who have <font color="blue">greater resources</font> and     experience than we do, may develop products or <font color="blue">technologies</font> that make ours     obsolete or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">life sciences</font> and other <font color="blue">technology</font> <font color="blue">industries</font> are <font color="blue">characterized by</font> rapid     <font color="blue">technological</font> change, and the area of sensory or taste <font color="blue">receptor research</font> is     a <font color="blue">rapidly evolving field</font></td>
    </tr>
    <tr>
      <td>Our future success will <font color="blue">depend on</font> our ability to     maintain a <font color="blue">competitive</font> position <font color="blue">with respect</font> to <font color="blue">technological</font> advances</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font><font color="blue">development</font>s <font color="blue">by others may</font> result in our flavors, flavor     <font color="blue">enhancers</font> or taste <font color="blue">modulators</font> and <font color="blue">technologies</font> becoming obsolete</td>
    </tr>
    <tr>
      <td>In particular, we face substantial <font color="blue">competition</font> from companies pursuing the     <font color="blue">commercialization</font> of products and <font color="blue">services relevant</font> to taste using more     <font color="blue">traditional methods</font> for the <font color="blue">discovery</font> of flavors, flavor <font color="blue">enhancers</font> and taste     <font color="blue">modulators</font>, or for the reduction of salt, sugar, MSG or bitter taste</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">competitors</font>  include  leading  flavor companies, such as International     Flavors &amp; Fragrances Inc, Givaudan SA, Symrise, Quest International and     Firmenich</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently compete</font> and <font color="blue">will continue</font> to compete in the future     with these companies in <font color="blue">collaborating with</font> and <font color="blue">selling flavor products</font> and     <font color="blue">technologies</font> to <font color="blue">manufacture</font>rs of <font color="blue">packaged food</font> and <font color="blue">beverage products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>of these companies have <font color="blue">substantially</font> greater capital resources, research     and  <font color="blue">development</font> resources and experience, <font color="blue">manufacturing</font> <font color="blue">capabilities</font>,     <font color="blue">regulatory</font>  expertise,  sales  and  marketing  resources,  established     <font color="blue"><font color="blue">relationship</font>s</font> with <font color="blue">consumer products</font> companies and production <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Savory flavor <font color="blue">enhancers</font>, <font color="blue">particularly</font> inosine monophosphate, or IMP, are     <font color="blue">commercially available</font>, and we <font color="blue">will <font color="blue">compete with</font></font> the companies that produce     these flavors</td>
    </tr>
    <tr>
      <td>IMP is <font color="blue">widely available</font> and is a <font color="blue">generally</font> accepted food     additive  by the <font color="blue">packaged food</font> and <font color="blue">beverage industry</font></td>
    </tr>
    <tr>
      <td>As a result, our     existing and future <font color="blue"><font color="blue">collaborator</font>s</font> may choose to <font color="blue">incorporate</font> IMP or similar     savory flavor <font color="blue">enhancers</font> into their <font color="blue">packaged food</font> and <font color="blue">beverage products</font>     instead of our savory flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td><font color="blue">In                                           </font>33     ______________________________________________________________________         addition, we may <font color="blue">compete with</font> bitter masking or <font color="blue">bitter blocking compounds</font>,     such as adenosine 5’ monophosphate, or AMP         We  may in  the  future  face <font color="blue">competition</font> from <font color="blue">life sciences</font> and other     <font color="blue">technology</font> companies and other <font color="blue">commercial enterprises</font></td>
    </tr>
    <tr>
      <td>These entities engage     as  we  do in bio<font color="blue">technology</font>, biology or <font color="blue">chemistry</font> and <font color="blue">could apply</font> this     <font color="blue">technology</font> to the <font color="blue">discovery</font> and <font color="blue">development</font> of flavors, flavor <font color="blue">enhancers</font> and     taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>We are aware of one other company, Linguagen Corp, a     privately-held company that we believe is involved in research on sweetness     <font color="blue">potentiators</font>, salt <font color="blue">substitutes</font> and bitter blockers, <font color="blue">specifically</font> AMP, and     has  announced  research  and  <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font> with several     companies</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that products developed as a result of our     <font color="blue">competitors</font>’ existing or future <font color="blue"><font color="blue">collaboration</font>s</font> will not <font color="blue">compete with</font> our     flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td><font color="blue">Universities </font>and public and <font color="blue">private research <font color="blue">institutions</font></font> are also potential     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>While  these  organizations  primarily  have <font color="blue">educational</font>     <font color="blue">objectives</font>, they may develop <font color="blue">proprietary</font> <font color="blue">technologies</font> related to the sense     of taste or secure <font color="blue">patent protection</font> that we may need for the <font color="blue">development</font> of     our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>We <font color="blue">may attempt</font> to license these <font color="blue">proprietary</font>     <font color="blue">technologies</font>, but these <font color="blue">licenses may</font> not be available to us on acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitors</font>,  either  alone or with their <font color="blue">collaborative</font> partners,     may succeed  in developing <font color="blue">technologies</font> or discovering flavors, flavor     <font color="blue">enhancers</font>  or  taste  <font color="blue">modulators</font>  that are more effective, safer, more     affordable or more easily <font color="blue">commercialize</font>d than ours, and our <font color="blue">competitors</font>     may obtain <font color="blue"><font color="blue">intellectual</font> property</font> protection or <font color="blue">commercialize</font> products sooner     than we do</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font><font color="blue">by others may</font> render our <font color="blue">product <font color="blue">candidates</font></font> or our     <font color="blue">technologies</font>  obsolete</td>
    </tr>
    <tr>
      <td>In addition, our current <font color="blue">product <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> are not prohibited from <font color="blue">entering into</font> research and     <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font>s with</font> <font color="blue">third parties</font> in any product     field</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">compete effectively would</font> have a <font color="blue">significant</font> adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be sued for <font color="blue">product <font color="blue">liability</font></font>, <font color="blue">which could</font> <font color="blue"><font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td>Because our business <font color="blue">strategy involves</font> the <font color="blue">development</font> and sale by our     <font color="blue"><font color="blue">collaborator</font>s</font> of <font color="blue">commercial products</font> <font color="blue">incorporating</font> our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font>, we may be sued for <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>We     may be held liable if any product we develop and <font color="blue">commercialize</font>, or any     product  our  <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">commercialize</font> that <font color="blue">incorporate</font>s any of our     flavors, flavor <font color="blue">enhancers</font> or taste <font color="blue">modulators</font>, causes injury or is found     otherwise unsuitable during product testing, <font color="blue">manufacturing</font>, marketing, sale     or <font color="blue">consumer use</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">safety studies</font> we must perform and the     <font color="blue">FEMA GRAS </font>de<font color="blue">termination</font> we must obtain prior to <font color="blue">incorporating</font> our flavors,     flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> into a <font color="blue">commercial product will</font> not     <font color="blue">protect us from</font> any <font color="blue">such <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>If we and our <font color="blue"><font color="blue">collaborator</font>s</font> commence sale of <font color="blue">commercial products</font> we will     need  to obtain <font color="blue">product <font color="blue">liability</font></font> insurance, and this <font color="blue">insurance may</font> be     <font color="blue">prohibitively expensive</font>, or may not <font color="blue">fully cover</font> our <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>to obtain sufficient insurance coverage at an acceptable cost or     otherwise  to protect against potential <font color="blue">product <font color="blue">liability</font></font> claims could     prevent or inhibit the <font color="blue">commercialization</font> of products developed by us or our     <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>We may be obligated to     indemnify our <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue"><font color="blue">collaborator</font>s</font> for product     <font color="blue">liability</font> or other losses they incur as a result of our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">indemnification</font> we receive from such     <font color="blue"><font color="blue">collaborator</font>s</font> for <font color="blue">product <font color="blue">liability</font></font> that does not arise from our flavors,     flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> may not be sufficient to satisfy our     <font color="blue">liability</font> to <font color="blue">injured parties</font></td>
    </tr>
    <tr>
      <td>If we are sued for any injury caused by our     flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> or products <font color="blue">incorporating</font> our     flavors, flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font>, our <font color="blue">liability</font> could exceed     our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">use <font color="blue">hazardous</font> materials</font></td>
    </tr>
    <tr>
      <td>Any claims relating to <font color="blue">improper handling</font>,     storage or disposal of these <font color="blue">materials could</font> be time consuming and costly</td>
    </tr>
    <tr>
      <td>Our <font color="blue">discovery</font> and <font color="blue">development</font> process requires our employees to routinely     handle  <font color="blue">hazardous</font>  chemical, radioactive and <font color="blue">biological materials</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">operations</font> also produce <font color="blue">hazardous</font> waste products</td>
    </tr>
    <tr>
      <td>Federal, state and local     laws and <font color="blue">regulations</font> govern the use, <font color="blue">manufacture</font>, storage, handling and     disposal of these materials</td>
    </tr>
    <tr>
      <td>As a result of the increase in size of our     <font color="blue">operations</font>, we were recently re-classified from a                                           34     ______________________________________________________________________         small  quantity to a large <font color="blue">quantity generator</font> of <font color="blue">hazardous</font> waste</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">reclassification may</font> result in <font color="blue">increased scrutiny</font> of our <font color="blue">operations</font> by the     <font color="blue">Environmental Protection Agency</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with applicable environmental</font>     laws and <font color="blue">regulations</font> may be expensive, and current or <font color="blue">future environmental</font>     <font color="blue">regulations</font> may impair our <font color="blue">discovery</font> and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>In  addition,  we  cannot  entirely  eliminate  the risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or discharge and any <font color="blue">resultant injury from</font> these materials</td>
    </tr>
    <tr>
      <td>Our property and <font color="blue">casualty policy</font> has very limited coverage for damages or     <font color="blue">cleanup costs</font> related to radioactive <font color="blue">contamination</font> and <font color="blue">pollutants</font> and our     general <font color="blue">liability</font> insurance policy excludes coverage for damages and fines     arising <font color="blue">from biological</font> or <font color="blue">hazardous</font> waste disposal or <font color="blue">contamination</font></td>
    </tr>
    <tr>
      <td>We do     not carry <font color="blue">specific biological</font> or <font color="blue">hazardous</font> waste insurance</td>
    </tr>
    <tr>
      <td>We may be forced     to  curtail <font color="blue">operations</font> or be sued for any injury or <font color="blue">contamination</font> that     results  from our use or the <font color="blue">use by others</font> of these materials, and our     <font color="blue">liability</font> may exceed our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>Risks Related To Our Common Stock         The price of our <font color="blue">common stock</font> is volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of bio<font color="blue">technology</font> companies historically     have <font color="blue">been highly volatile</font>, and the market has from time to time experienced     <font color="blue">significant</font>  price  and  <font color="blue">volume <font color="blue">fluctuations</font></font> that are unrelated to the     operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>Since our <font color="blue">initial public</font>     offering  in  June 2004, the price of our <font color="blue">common stock</font> has <font color="blue">ranged from</font>     approximately dlra5 per share to approximately dlra23 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>     of our <font color="blue">common stock</font> may fluctuate in response to many factors, including:         •                  <font color="blue">development</font>s related to the <font color="blue">FEMA GRAS </font>de<font color="blue">termination</font> and     international <font color="blue"><font color="blue">regulatory</font> approval</font> of our products;       •                  <font color="blue">development</font>s <font color="blue">concerning</font> our <font color="blue">collaborative</font> <font color="blue">agreement</font>s;       •                  <font color="blue">announcements</font> of <font color="blue">technological</font> innovations by us or     others;       •                  <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights;       •                  results of safety evaluation of our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font>;       •                  results of consumer <font color="blue">acceptance</font> testing of our flavors,     flavor <font color="blue">enhancers</font> and taste <font color="blue">modulators</font> by our <font color="blue"><font color="blue">collaborator</font>s</font>;       •                   delays in <font color="blue">commercialization</font> of our flavors, flavor     <font color="blue">enhancers</font> and taste <font color="blue">modulators</font>;       •                   future  sales  of  our  common  stock  by existing     <font color="blue">stockholders</font>;       •                  comments by <font color="blue">securities analysts</font>;       •                  <font color="blue">general market conditions</font>;       •                  <font color="blue">fluctuations</font> in our operating results;       •                  <font color="blue">government regulation</font>;       •                  failure of any of our flavors, flavor <font color="blue">enhancers</font> or taste     <font color="blue">modulators</font>, if approved, to achieve <font color="blue">commercial success</font>; and       •                  public concern as to the safety of our flavors, flavor     <font color="blue">enhancers</font>, and taste <font color="blue">modulators</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">charter documents</font> and under <font color="blue">Delaware </font>law     may make  an  <font color="blue">acquisition</font>  of  us more complicated and the removal and     <font color="blue">replacement</font> of our <font color="blue">directors</font> and <font color="blue">management</font> more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and     bylaws, as well as provisions of <font color="blue">Delaware </font>law, could make it more <font color="blue">difficult</font>     for  a  third  party to acquire us, even if doing so <font color="blue">would benefit</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may also</font> make it <font color="blue">difficult</font> for <font color="blue">stockholders</font>     to  remove  and  replace  our board of <font color="blue">directors</font> and <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions:         •                  authorize the issuance of “blank check” preferred stock     by  our  board of <font color="blue">directors</font>, without stockholder approval, <font color="blue">which could</font>     increase the number of <font color="blue">outstanding shares</font> and prevent or delay a takeover     attempt;       •                  limit who may call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font>;       •                  prohibit stockholder action by written consent, thereby     requiring  all  stockholder  actions  to  be taken at a meeting of our     <font color="blue">stockholders</font>; and                                           35     ______________________________________________________________________         •                  <font color="blue">establish advance</font> notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for     election to the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be     acted <font color="blue">upon at stockholder meetings</font></td>
    </tr>
    <tr>
      <td>In  addition,  the <font color="blue">requirements</font> of Section 203 of the <font color="blue">Delaware </font>General     Corporation  Law  <font color="blue">may discourage</font>,  delay or prevent a <font color="blue">third party from</font>     acquiring us</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">shareholder</font>  rights  plan may hinder or prevent change of control     <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">shareholder</font> rights plans <font color="blue">may discourage</font> <font color="blue">transactions</font> involving an actual     or potential change in our ownership</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font>     <font color="blue">may issue shares</font> of <font color="blue">preferred stock without</font> any <font color="blue">further action by</font> you</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">issuances may</font> have the effect of delaying or preventing a change in our     ownership</td>
    </tr>
    <tr>
      <td>If  changes  in  our ownership are discouraged, delayed or     prevented, it would be more <font color="blue">difficult</font> for our <font color="blue">current board</font> of <font color="blue">directors</font> to     be removed and replaced, even if you and other <font color="blue">stockholders</font> believe such     actions are in the <font color="blue">best interests</font> of us and our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If our officers, <font color="blue">directors</font> and largest <font color="blue">stockholders</font> choose to act together,     they may be able to control our <font color="blue">management</font> and <font color="blue">operations</font>, acting in their     <font color="blue">best interests</font> and not <font color="blue">necessarily</font> the interests of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of February </font>28, 2006, our executive officers, <font color="blue">directors</font> and <font color="blue">stockholders</font>     with at least 5prca of our <font color="blue">stock together beneficially</font> owned approximately 27prca     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If these officers, <font color="blue">directors</font> and principal <font color="blue">stockholders</font>     act together, they will be able to exert a <font color="blue">significant</font> degree of influence     over our <font color="blue">management</font> and affairs and <font color="blue">over matters</font> requiring stockholder     approval, including the election of <font color="blue">directors</font> and approval of mergers or     other business combination <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>The interests of this <font color="blue">concentration</font>     of <font color="blue">ownership may</font> not <font color="blue">always coincide with</font> our interests or the interests of     investors in this offering or other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>For instance, officers,     <font color="blue">directors</font> and principal <font color="blue">stockholders</font>, acting together, could cause us to     <font color="blue">enter into</font> <font color="blue">transactions</font> or <font color="blue">agreement</font>s that we would not otherwise consider</td>
    </tr>
    <tr>
      <td>Similarly, this <font color="blue">concentration</font> of <font color="blue">ownership may</font> have the effect of delaying     or preventing a change in control of our <font color="blue">company otherwise favored by</font> our     other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of <font color="blue">ownership could depress</font> our stock     price</td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">never paid cash dividends on</font> our <font color="blue">capital stock</font> and we do not     anticipate <font color="blue">paying dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">paid no cash dividends on</font> any of our classes of <font color="blue">capital stock</font> to     date, and we <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to fund     the <font color="blue">development</font> and growth of our business</td>
    </tr>
    <tr>
      <td>In addition, the terms of any     <font color="blue">future debt</font> or credit <font color="blue">facility may preclude us from paying</font> any dividends</td>
    </tr>
    <tr>
      <td>As     a result, capital <font color="blue">appreciation</font>, if any, of our <font color="blue">common stock</font> will be your     sole source of <font color="blue">potential gain</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
  </tbody>
</table>